Multi Drug and Other Forms of Drug Resistant Tuberculosis Are Uncommon among Treatment Naïve Tuberculosis Patients in Tanzania

Background Surveillance and effective management of drug resistance is important to sustaining tuberculosis (TB) control efforts. We aimed to determine resistance rates to first line anti tuberculosis drugs and to describe factors associated with the resistance to any of the first line anti tuberculosis drugs in Dar es Salaam Tanzania. Materials Newly diagnosed, TB patients with neither history of tuberculosis treatment nor isoniazid prophylaxis were included into the study. Sputum specimens were cultured on either mycobacteria growth indicator tube 960 (MGIT 960) or Lowenstein Jenstein (LJ) medium supplemented with either glycerol (GLJ) or pyruvate (PLJ). Drug susceptibility for isoniazid, rifampicin, streptomycin and ethambutol was determined by either Lowenstein–Jensen (LJ) medium or mycobacteria growth indicator tube 960 (MGIT 960). Results A total of 933 newly diagnosed TB patients, were included into the study. Multi drug resistance (MDR) tuberculosis was detected among 2 (0.2%) patients. Resistance to any of the four tested drugs was detected among 54 (5.8%) patients. Mono-resistance to isoniazid, rifampicin, streptomycin and ethambutol were 21(2.3%), 3 (0.3%), 13 (1.4%), 9 (1.0%) respectively. Conclusion Primary resistance to first line anti tuberculosis drugs is still low in this setting. Continued vigilance including periodic national surveillance of anti-tuberculosis resistance is recommended.

[1]  W. Fawzi,et al.  Anemia at the Initiation of Tuberculosis Therapy Is Associated with Delayed Sputum Conversion among Pulmonary Tuberculosis Patients in Dar-es-Salaam, Tanzania , 2014, PloS one.

[2]  N. Clumeck,et al.  EPIDEMIOLOGY OF MDR-TB IN A BELGIAN INFECTIOUS DISEASES UNIT: A 15 YEARS REVIEW , 2013, Acta clinica Belgica.

[3]  V. Jarlier,et al.  A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[4]  M. Joloba,et al.  Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis Patients in Uganda: Results of the First National Survey , 2013, PloS one.

[5]  K. Dooley,et al.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? , 2013, The Journal of infectious diseases.

[6]  D. Sauvageot,et al.  The impact of total antioxidant capacity on pulmonary function in asthma patients. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  K. Floyd,et al.  Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. , 2012, Bulletin of the World Health Organization.

[8]  S. Egwaga,et al.  National anti-tuberculosis drug resistance study in Tanzania. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  K. Kam,et al.  Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance , 2009, The Lancet.

[10]  M. Matee,et al.  Anti‐TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  W. Fawzi,et al.  Primary antimicrobial resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative patients in Dar es Salaam Tanzania , 2008, BMC Research Notes.

[12]  F. Drobniewski,et al.  Increasing antituberculosis drug resistance in the United Kingdom: analysis of national surveillance data , 2008, BMJ : British Medical Journal.

[13]  V. Chihota,et al.  Increasing drug resistant tuberculosis in the UK , 2008, BMJ : British Medical Journal.

[14]  D. van Soolingen,et al.  M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV- infected and non-HIV-infected patients in northern Tanzania , 2007, BMC microbiology.

[15]  C. Dye,et al.  Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) , 1998 .

[16]  J. Bennedsen,et al.  DNA fingerprinting and phenotyping of Mycobacterium tuberculosis isolates from human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients in Tanzania , 1995, Journal of clinical microbiology.

[17]  M. Becerra,et al.  High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  M. Aziz,et al.  Guidelines for surveillance of drug resistance in tuberculosis , 2009 .

[19]  Lung Disease,et al.  Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance , 1997 .